A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ULTRA-2
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Nov 2016 Results of post hoc analysis of this and other five studies (CLASSIC-I, GAIN, CHARM, EXTEND, ULTRA 1 AND ULTRA 2) published in the Alimentary Pharmacology and Therapeutics
    • 19 May 2015 Results (post hoc analysis: durable remission and response) presented at the Digestive Disease Week 2015.
    • 21 May 2013 Tolerability results from a pooled analysis presented at the Digestive Disease Week 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top